(Q36847262)

16 August 2017

1 reference

title

Death in the substantia nigra: a motor tragedy (English)

1 reference

16 August 2017

1 reference

3

Giuseppe Di Giovanni

1 reference

16 August 2017

Ennio Esposito

1

1 reference

PubMed ID

17563251

16 August 2017

Vincenzo Di Matteo

series ordinal

2

1 reference

16 August 2017

1 June 2007

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

16 August 2017

1 reference

16 August 2017

7

1 reference

16 August 2017

6

1 reference

16 August 2017

677-697

1 reference

Effects of community based nurses specialising in Parkinson's disease on health outcome and costs: randomised controlled trial

16 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

A review of the health-related quality of life and economic impact of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Parkinson's disease: a major hypokinetic basal ganglia disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Dopamine cell replacement: Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Stages in the development of Parkinson's disease-related pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Optimising levodopa therapy for the management of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Present and future drug treatment for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Microglia in neurodegeneration: molecular aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

The pathogenesis of cell death in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

p53 mediates nontranscriptional cell death in dopaminergic cells in response to proteasome inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Serotonergic mechanisms in Parkinson's disease: opposing results from preclinical and clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Morphology and distribution of dopaminergic neurons intrinsic to the human striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Cortical and striatal expression of tyrosine hydroxylase mRNA in neonatal and adult mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Dopamine neuron systems in the brain: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

DEMONSTRATION AND MAPPING OUT OF NIGRO-NEOSTRIATAL DOPAMINE NEURONS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Golgi study of the primate substantia nigra. I. Quantitative morphology and typology of nigral neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Localization of monoamines in the lower brain stem.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Chemical Anatomy of the Brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Immunocytochemical studies of GABAergic neurons in rat basal ganglia and their relations to other neuronal systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Midbrain dopaminergic neurons (nuclei A8, A9, and A10): three-dimensional reconstruction in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Selective blockade of serotonin-2C/2B receptors enhances mesolimbic and mesostriatal dopaminergic function: a combined in vivo electrophysiological and microdialysis study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Acute effects of 6-hydroxydopamine on dopaminergic neurons of the rat substantia nigra pars compacta in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Ventral mesencephalic neurons containing both cholecystokinin- and tyrosine hydroxylase-like immunoreactivities project to forebrain regions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Morphological and physiological properties of parvalbumin- and calretinin-containing gamma-aminobutyric acidergic neurons in the substantia nigra.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

How to make a mesodiencephalic dopaminergic neuron

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Re-examining the ontogeny of substantia nigra dopamine neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Making connections: the development of mesencephalic dopaminergic neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Developmental origin and fate of meso-diencephalic dopamine neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Genetic networks controlling the development of midbrain dopaminergic neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Dopamine neuron agenesis in Nurr1-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

A second independent pathway for development of mesencephalic dopaminergic neurons requires Lmx1b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Cooperative transcription activation by Nurr1 and Pitx3 induces embryonic stem cell maturation to the midbrain dopamine neuron phenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Molecular programming of stem cells into mesodiencephalic dopaminergic neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Midbrain-derived neural stem cells: from basic science to therapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Ageing and Parkinson's disease: substantia nigra regional selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Nonsteroidal anti-inflammatory drugs in Parkinson's disease: possible involvement of quinone formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Role of oxidative changes in the degeneration of dopamine terminals after injection of neurotoxic levels of dopamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Regional vulnerability of mesencephalic dopaminergic neurons prone to degenerate in Parkinson's disease: a post-mortem study in human control subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

The homeodomain transcription factor Pitx3 facilitates differentiation of mouse embryonic stem cells into AHD2-expressing dopaminergic neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Gene expression profiling of rat midbrain dopamine neurons: implications for selective vulnerability in parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Decreased susceptibility to oxidative stress underlies the resistance of specific dopaminergic cell populations to paraquat-induced degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

A proposed dual role of neuromelanin in the pathogenesis of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Inverse relationship between the contents of neuromelanin pigment and the vesicular monoamine transporter-2: human midbrain dopamine neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Macromolecular crowding: obvious but underappreciated

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

The cellular pathology of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Recessive Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Unraveling the pathogenesis of Parkinson's disease--the contribution of monogenic forms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Molecular pathogenesis of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Parkinsonism genes: culprits and clues

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Microglia in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Oxidative stress and inflammation in Parkinson's disease: is there a causal link?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Inflammation and neurodegeneration in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Role of inflammation in neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

To be or not to be (inflamed)--is that the question in anti-inflammatory drug therapy of neurodegenerative disorders?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Presence of reactive microglia in monkey substantia nigra years after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Temporal and sequential analysis of microglia in the substantia nigra following medial forebrain bundle axotomy in rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Different parkinsonism models produce a time-dependent induction of COX-2 in the substantia nigra of rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Cyclooxygenases mRNA and protein expression in striata in the experimental mouse model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to mouse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Effects of repeated systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to mice on interleukin-1beta and nerve growth factor in the striatum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Neuritic beading induced by activated microglia is an early feature of neuronal dysfunction toward neuronal death by inhibition of mitochondrial respiration and axonal transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Neural grafting in a rat model of Huntington's disease: progressive neurochemical changes after neostriatal ibotenate lesions and striatal tissue grafting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Down-regulation of microglial activation may represent a practical strategy for combating neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Novel anti-inflammatory therapy for Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Non-steroidal anti-inflammatory drugs (NSAIDs) and other anti-inflammatory agents in the treatment of neurodegenerative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappaB activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Inhibition of activator protein 1 activity and neoplastic transformation by aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Sodium salicylate enhances the expression of cyclooxygenase-2 in endotoxin-stimulated human mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

The molecular biology of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Suppression of inducible cyclooxygenase 2 gene transcription by aspirin and sodium salicylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Aspirin and other cyclooxygenase inhibitors: new therapeutic insights

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Neuroprotective effects of non-steroidal anti-inflammatory drugs by direct scavenging of nitric oxide radicals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Effects of aspirin on number, activity and inducible nitric oxide synthase of endothelial progenitor cells from peripheral blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Aspirin protects striatal dopaminergic neurons from neurotoxin-induced degeneration: an in vivo microdialysis study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

7-nitroindazole protects striatal dopaminergic neurons against MPP+-induced degeneration: an in vivo microdialysis study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Non-steroidal anti-inflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Acetaminophen and aspirin inhibit superoxide anion generation and lipid peroxidation, and protect against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Acetylsalicylic acid and acetaminophen protect against MPP+-induced mitochondrial damage and superoxide anion generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Indomethacin protects against neurodegeneration caused by MPTP intoxication in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

The COX-2 inhibitor parecoxib produces neuroprotective effects in MPTP-lesioned rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

The role of the immune system in neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Cell death by necrosis: towards a molecular definition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Energy requirement for caspase activation and neuronal cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Key note lecture: toward a mechanistic taxonomy for cell death programs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Apoptosis, excitotoxicity, and neuropathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Apoptosis and brain development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Apoptosis in Parkinson's disease: signals for neuronal degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Cell death and apoptosis regulating proteins in Parkinson's disease--a cautionary note.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Evidence of apoptosis in the subventricular zone and rostral migratory stream in the MPTP mouse model of Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Caspase‐3 dependent proteolytic activation of protein kinase Cδ mediates and regulates 1‐methyl‐4‐phenylpyridinium (MPP+)‐induced apoptotic cell death in dopaminergic cells: relevance to oxidative stress in dopaminergic degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

6-Hydroxydopamine increases the level of TNFalpha and bax mRNA in the striatum and induces apoptosis of dopaminergic neurons in hemiparkinsonian rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Targeted expression of BCL-2 attenuates MPP+ but not 6-OHDA induced cell death in dopaminergic neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

For the long run: maintaining germinal niches in the adult brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Enriched environment increases neurogenesis in the adult rat dentate gyrus and improves spatial memory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Milestones of neuronal development in the adult hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Evidence for neurogenesis in the adult mammalian substantia nigra

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Stem cell therapy for human neurodegenerative disorders-how to make it work

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Dopamine and adult neurogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Dopaminergic substantia nigra neurons project topographically organized to the subventricular zone and stimulate precursor cell proliferation in aged primates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Dopamine depletion impairs precursor cell proliferation in Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Enhanced de novo neurogenesis and dopaminergic neurogenesis in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease-like mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

No evidence for new dopaminergic neurons in the adult mammalian substantia nigra

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Enriched environment induces cellular plasticity in the adult substantia nigra and improves motor behavior function in the 6-OHDA rat model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

In vivo induction of massive proliferation, directed migration, and differentiation of neural cells in the adult mammalian brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Platelet-derived growth factor (PDGF-BB) and brain-derived neurotrophic factor (BDNF) induce striatal neurogenesis in adult rats with 6-hydroxydopamine lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Serotonin involvement in the basal ganglia pathophysiology: could the 5-HT2C receptor be a new target for therapeutic strategies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

Novel pharmacological targets for the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

New dopaminergic neurons in Parkinson's disease striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.677

21 January 2018

Identifiers

DOI

10.1586/14737175.7.6.677

1 reference

16 August 2017

1 reference

PubMed ID

17563251